BioNTech

At its AI Day, BioNTech highlighted InstaDeep's new near-exascale supercomputer, Kyber, with the aim of enabling BioNTech to compute at scale. The release describes this as the introduction of a new near-exascale supercomputer.

At the same AI Day, BioNTech unveiled novel AI Bayesian Flow Network models for protein sequence generation. The release describes the update as the launch of a novel BFN generative model.

InstaDeep's chief executive, speaking as part of BioNTech's AI Day, said a key focus is the DeepChain multiomics design platform. He said DeepChain is now open for external partnerships after successful application to several projects, including the mRNA-encoded antibody RiboMab platform.

BioNTech's AI Day release says the company is highlighting progress in deploying AI across its immunotherapy pipeline, including immunohistochemistry, DNA and RNA sequencing, proteomics, protein design and laboratory functional validation.

BioNTech and InstaDeep announced an agreement under which BioNTech will acquire InstaDeep, described as a technology company in artificial intelligence and machine learning. The release says BioNTech-trained AI and machine-learning models are planned to be embedded across discovery platforms, and that the companies have jointly developed multiple end-to-end AI-based applications. Closing was still expected in the first half of 2023.

Partners: InstaDeep

BioNTech and InstaDeep announced a computational method that analyzes sequencing data and predicts high-risk SARS-CoV-2 variants. The Early Warning System, developed in the collaboration, is based on artificial-intelligence immune-escape and fitness metrics. The release says that during a trial period the system identified more than 90 percent of WHO-designated variants on average two months in advance.

Partners: InstaDeep

BioNTech and InstaDeep announced a multi-year collaboration to apply artificial intelligence and machine learning to novel immunotherapies for cancers and infectious diseases. They said they will form a joint AI Innovation Lab in London and Mainz covering drug discovery and design, protein engineering, manufacturing and supply-chain optimization. The release also says BioNTech plans to use AI and machine-learning applications to optimize manufacturing and supply-chain processes.

Partners: InstaDeep